Welwyn Garden City (20th August 2012) – Cresset BioMolecular Discovery is delighted to announce the appointment of Dr David Bardsley to the newly created role of Sales Director at Cresset Group. David joins Cresset from Synergy Health Plc where, as Sales Director of the Healthcare Solutions division, he was responsible for the organisation delivering product solutions to healthcare professionals and institutions.
“This new appointment marks Cresset’s commitment to ensuring companies have the right channels to access software tools and consulting services which are able to streamline their discovery process and tighten their IP position” said Rob Scoffin, Chief Executive Officer of Cresset.
“I am pleased to be joining Cresset BioMolecular Discovery at such an exciting time in their growth strategy. Cresset’s solutions and services have proven successful for many clients and this success can be duplicated to parallel markets and expanded geographies” said David.
David has extensive knowledge in software and technology solutions, with more than twenty years of commercial experience in the scientific market. Prior to Cresset, David was responsible for business development and strategic commercial growth, with both Symyx Technologies and CambridgeSoft. David has a PhD and BSc in Microbiology from the University of Wales Cardiff.
For further information, please visit www.cresset-group.com
About Cresset Group Ltd
Cresset develops software for calculating and comparing the molecular field characteristics of chemical compounds. Field technology uses the surface properties of molecules to evaluate their activities and properties, rather than relying on 2D structure similarity, which enables Cresset’s customers to find more interesting, novel and relevant results than other methods. Cresset’s fields provide a smarter, structure independent way of hit-finding, lead switching and lead optimization in drug discovery and other chemistry-based research projects. Cresset’s field technologies have been successfully applied to a very wide range of target classes, with and without structural information, on over 100 projects for major pharmaceutical and biotechnology companies. www.cresset-group.com.